A Double-blind, Randomized, Controlled Trial of Quetiapine Versus Haloperidol for the Treatment of Delirium

Model scores of the 29,894 trials active now.

Model score 12% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 17% of the time (276 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2012-07-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: to determinepurpose ofthe purposedetermine whetherstudy is
  Phrases that lowered it: and safetyefficacy andfemalemalecompare
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Phase: 3 (lowers risk) · Design
• Responsible party: not given (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Disease area, neurology: Yes (raises risk) · Disease area
• Design: parallel (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports with a death: 14.9% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports before start: 22189 (raises risk) · Drug's FDA history
• Blinding: quadruple (lowers risk) · Design
• Sponsor's past trials: 0 (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Maximum age: 75 (lowers risk) · Who can join
• Drug's FAERS reports marked serious: 77.4% (lowers risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Quetiapine Versus Haloperidol in the Management of Hyperactive Delirium NCT05690698 · started 2023 · scored riskier than 14% of active trials completed
• Efficacy of Quetiapine for Pediatric Delirium NCT02056171 · started 2015 · scored riskier than 47% of active trials terminated
• Trial Comparing Haloperidol, Quetiapine and Placebo in the Pharmacological Treatment of Delirium NCT01811459 · started 2013 · scored riskier than 68% of active trials completed
• Quetiapine in Prevention of Delirium NCT05793632 · started 2023 · scored riskier than 13% of active trials completed
• Methylphenidate, Rivastigmine or Haloperidol in Hypoactive Delirium in Intensive Care Patients NCT00599287 · started 2008 · scored riskier than 17% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.